Back

CKD Evaluation and Management

KDIGO has updated the 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). KDIGO is now preparing the final version of the 2023 CKD Guideline based on feedback received during public review. 

The update to the CKD Guideline is intended for healthcare professionals involved in the provision of kidney care, people with suspected or diagnosed CKD and their carers, as well as policymakers and commissioners of CKD services. The aim is to generate a useful resource that clearly and concisely addresses relevant questions with actionable recommendations based on a formal evidence review and consensus-based practice points to guide clinical practice.  

The development of this guideline follows an explicit process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant trials. Appraisal of the quality of the evidence and the strength of recommendations for graded recommendations followed the GRADE approach. Practice points are also issued when a clinical question was not deemed a high priority for systematic review to help readers implement the guidance from graded recommendations (e.g., frequency of monitoring, provision of standard care (such as regular clinic visits), referral to specialist care, etc.), or for issuing “good practice statements” when the alternative is considered to be absurd. A robust introduction from the Co-Chairs sets the stage for this important guideline update. Special considerations, including pediatric, older adult, and international considerations, and population-level associations with risk presented as heatmaps from the Chronic Kidney Disease Prognosis Consortium (CKD-PC) are also discussed.

The 2023 CKD Guideline is co-chaired by Dr. Adeera Levin (Canada) and Dr. Paul Stevens (United Kingdom).